By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –The Scripps Translational Science Institute (STSI) and partner Sangamo BioSciences will use a $7.9 million grant from the National Institutes of Health to fund a multidisciplinary study of a region of the human genome thought to be involved in heart disease.

STSI and Sangamo will partner to use induced pluripotent stem (IPS) cells and zinc finger nuclease (ZFN)-based genetic editing in a "disease-in-a-dish" study of the 9p21 region of the genome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.